Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets.
Identifieur interne : 000212 ( PubMed/Corpus ); précédent : 000211; suivant : 000213Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets.
Auteurs : Grace L. Chen ; Elaine W. Lamirande ; Hong Jin ; George Kemble ; Kanta SubbaraoSource :
- Virology [ 1096-0341 ] ; 2010.
English descriptors
- KwdEn :
- Adaptation, Physiological, Animals, Cold Temperature, Female, Ferrets, Influenza A Virus, H2N2 Subtype (genetics), Influenza A Virus, H2N2 Subtype (immunology), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Lung (virology), Male, Mice, Mice, Inbred BALB C, Mutation, Orthomyxoviridae Infections (prevention & control), Orthomyxoviridae Infections (virology), Vaccines, Attenuated, Virus Replication.
- MESH :
- chemical , adverse effects : Influenza Vaccines.
- genetics : Influenza A Virus, H2N2 Subtype.
- immunology : Influenza A Virus, H2N2 Subtype, Influenza Vaccines.
- prevention & control : Orthomyxoviridae Infections.
- virology : Lung, Orthomyxoviridae Infections.
- Adaptation, Physiological, Animals, Cold Temperature, Female, Ferrets, Male, Mice, Mice, Inbred BALB C, Mutation, Vaccines, Attenuated, Virus Replication.
Abstract
We studied the attenuation, immunogenicity and efficacy of the cold-adapted A/Ann Arbor/6/60 (AA ca) (H2N2) virus in mice and ferrets to evaluate its use in the event of an H2 influenza pandemic. The AA ca virus was restricted in replication in the respiratory tract of mice and ferrets. In mice, 2 doses of vaccine elicited a >4-fold rise in hemagglutination-inhibition (HAI) titer and resulted in complete inhibition of viral replication following lethal homologous wild-type virus challenge. In ferrets, a single dose of the vaccine elicited a >4-fold rise in HAI titer and conferred complete protection against homologous wild-type virus challenge in the upper respiratory tract. In both mice and ferrets, the AA ca virus provided significant protection from challenge with heterologous H2 virus challenge in the respiratory tract. The AA ca vaccine is safe, immunogenic, and efficacious against homologous and heterologous challenge in mice and ferrets, supporting the evaluation of this vaccine in clinical trials.
DOI: 10.1016/j.virol.2009.12.003
PubMed: 20034647
Links to Exploration step
pubmed:20034647Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets.</title>
<author><name sortKey="Chen, Grace L" sort="Chen, Grace L" uniqKey="Chen G" first="Grace L" last="Chen">Grace L. Chen</name>
<affiliation><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA. chengra@niaid.nih.gov</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name>
</author>
<author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
</author>
<author><name sortKey="Kemble, George" sort="Kemble, George" uniqKey="Kemble G" first="George" last="Kemble">George Kemble</name>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20034647</idno>
<idno type="pmid">20034647</idno>
<idno type="doi">10.1016/j.virol.2009.12.003</idno>
<idno type="wicri:Area/PubMed/Corpus">000212</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000212</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets.</title>
<author><name sortKey="Chen, Grace L" sort="Chen, Grace L" uniqKey="Chen G" first="Grace L" last="Chen">Grace L. Chen</name>
<affiliation><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA. chengra@niaid.nih.gov</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name>
</author>
<author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
</author>
<author><name sortKey="Kemble, George" sort="Kemble, George" uniqKey="Kemble G" first="George" last="Kemble">George Kemble</name>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</author>
</analytic>
<series><title level="j">Virology</title>
<idno type="eISSN">1096-0341</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptation, Physiological</term>
<term>Animals</term>
<term>Cold Temperature</term>
<term>Female</term>
<term>Ferrets</term>
<term>Influenza A Virus, H2N2 Subtype (genetics)</term>
<term>Influenza A Virus, H2N2 Subtype (immunology)</term>
<term>Influenza Vaccines (adverse effects)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Lung (virology)</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mutation</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Orthomyxoviridae Infections (virology)</term>
<term>Vaccines, Attenuated</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term>
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adaptation, Physiological</term>
<term>Animals</term>
<term>Cold Temperature</term>
<term>Female</term>
<term>Ferrets</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mutation</term>
<term>Vaccines, Attenuated</term>
<term>Virus Replication</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We studied the attenuation, immunogenicity and efficacy of the cold-adapted A/Ann Arbor/6/60 (AA ca) (H2N2) virus in mice and ferrets to evaluate its use in the event of an H2 influenza pandemic. The AA ca virus was restricted in replication in the respiratory tract of mice and ferrets. In mice, 2 doses of vaccine elicited a >4-fold rise in hemagglutination-inhibition (HAI) titer and resulted in complete inhibition of viral replication following lethal homologous wild-type virus challenge. In ferrets, a single dose of the vaccine elicited a >4-fold rise in HAI titer and conferred complete protection against homologous wild-type virus challenge in the upper respiratory tract. In both mice and ferrets, the AA ca virus provided significant protection from challenge with heterologous H2 virus challenge in the respiratory tract. The AA ca vaccine is safe, immunogenic, and efficacious against homologous and heterologous challenge in mice and ferrets, supporting the evaluation of this vaccine in clinical trials.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20034647</PMID>
<DateCompleted><Year>2010</Year>
<Month>03</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>10</Month>
<Day>08</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0341</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>398</Volume>
<Issue>1</Issue>
<PubDate><Year>2010</Year>
<Month>Mar</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Virology</Title>
<ISOAbbreviation>Virology</ISOAbbreviation>
</Journal>
<ArticleTitle>Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets.</ArticleTitle>
<Pagination><MedlinePgn>109-14</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virol.2009.12.003</ELocationID>
<Abstract><AbstractText>We studied the attenuation, immunogenicity and efficacy of the cold-adapted A/Ann Arbor/6/60 (AA ca) (H2N2) virus in mice and ferrets to evaluate its use in the event of an H2 influenza pandemic. The AA ca virus was restricted in replication in the respiratory tract of mice and ferrets. In mice, 2 doses of vaccine elicited a >4-fold rise in hemagglutination-inhibition (HAI) titer and resulted in complete inhibition of viral replication following lethal homologous wild-type virus challenge. In ferrets, a single dose of the vaccine elicited a >4-fold rise in HAI titer and conferred complete protection against homologous wild-type virus challenge in the upper respiratory tract. In both mice and ferrets, the AA ca virus provided significant protection from challenge with heterologous H2 virus challenge in the respiratory tract. The AA ca vaccine is safe, immunogenic, and efficacious against homologous and heterologous challenge in mice and ferrets, supporting the evaluation of this vaccine in clinical trials.</AbstractText>
<CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Grace L</ForeName>
<Initials>GL</Initials>
<AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA. chengra@niaid.nih.gov</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lamirande</LastName>
<ForeName>Elaine W</ForeName>
<Initials>EW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jin</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kemble</LastName>
<ForeName>George</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Subbarao</LastName>
<ForeName>Kanta</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>ZIA AI000933-07</GrantID>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>12</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Virology</MedlineTA>
<NlmUniqueID>0110674</NlmUniqueID>
<ISSNLinking>0042-6822</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000222" MajorTopicYN="N">Adaptation, Physiological</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003080" MajorTopicYN="N">Cold Temperature</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005289" MajorTopicYN="N">Ferrets</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053121" MajorTopicYN="N">Influenza A Virus, H2N2 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year>
<Month>08</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2009</Year>
<Month>09</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2009</Year>
<Month>12</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>12</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>12</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>3</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">20034647</ArticleId>
<ArticleId IdType="pii">S0042-6822(09)00788-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.virol.2009.12.003</ArticleId>
<ArticleId IdType="pmc">PMC2823816</ArticleId>
<ArticleId IdType="mid">NIHMS167498</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Expert Rev Vaccines. 2004 Dec;3(6):643-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15606348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2000 Mar;181(3):1133-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10720541</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e360</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbiol Rev. 1992 Mar;56(1):152-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1579108</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viral Immunol. 2002;15(2):295-323</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12081014</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Med Virol. 1999 Oct-Dec;9(4):237-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10578119</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1999 Dec;80 ( Pt 12):3167-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10567648</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 1992;176:75-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1600756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull World Health Organ. 1999;77(10):820-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10593030</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1989 Nov;63(11):4603-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2795713</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2003 Feb 1;306(1):18-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12620793</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1978 Jun 1;87(1):13-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">664248</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1982 Dec;146(6):780-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7142749</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1969 Mar;102(3):728-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5773321</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Med. 2000;51:407-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10774473</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1997 Aug;176 Suppl 1:S14-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9240688</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 1994;135(1-2):101-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8198436</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Aug 12;26(34):4299-303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18582523</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1982 Nov;38(2):610-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6982866</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2009 Jul 10;325(5937):197-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19465683</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2009 Jun 18;459(7249):931-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19525932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2003 Jul;70(3):391-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12767002</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1967 Feb 11;213(5076):612-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6040602</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1982 Oct;38(1):218-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6982860</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Genes. 2008 Aug;37(1):16-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18454312</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Avian Dis. 2007 Mar;51(1 Suppl):425-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17494599</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2008 Aug 15;378(1):123-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18585748</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1973 Jan;7(1):119-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16558072</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2007 Nov;3(11):e167</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17997603</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1993 Jun;194(2):781-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7684877</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000212 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000212 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:20034647 |texte= Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20034647" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
This area was generated with Dilib version V0.6.33. |